C
FDMT icon

Covestor’s 4D Molecular Therapeutics FDMT Stock Holding History

Covestor’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Buy
34
+18
+113% +$175 ﹤0.01% 2591
2026
Q1 		$0 Hold
16
– – ﹤0.01% 2421
2025
Q4 		$0 Hold
16
– – ﹤0.01% 2403
2025
Q3 		$0 Hold
16
– – ﹤0.01% 2433
2025
Q2 		$0 Sell
16
-1
-6% -$4 ﹤0.01% 2376
2025
Q1 		$0 Buy
17
+9
+113% +$42 ﹤0.01% 2385
2024
Q4 		$0 Buy
8
+1
+14% +$8 ﹤0.01% 2396
2024
Q3 		$0 Buy
7
+3
+75% +$50 ﹤0.01% 2380
2024
Q2 		$0 Hold
4
– – ﹤0.01% 2396
2024
Q1 		$0 Buy
+4
New +$102 ﹤0.01% 2393

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Covestor's FDMT Position: Q2 2026 in Review

Covestor increased its 4D Molecular Therapeutics (FDMT) stake by 113% in Q2 2026, buying an estimated $175 and bringing the position to 34 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2591.

Covestor first reported a position in FDMT in Q1 2024 and has held it in 10 quarters since. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Covestor held 34 shares of 4D Molecular Therapeutics worth $0 as of Q2 2026.
  • Covestor bought 18 4D Molecular Therapeutics shares in Q2 2026, an estimated $175.
  • 4D Molecular Therapeutics made up ﹤0.01% of Covestor's portfolio in Q2 2026, its #2591 holding.
  • Covestor first reported a position in 4D Molecular Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • 157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Covestor's 13F filing for Q2 2026, filed 7 Aug 2026.